Spurring Innovation While Economizing On R&D Spending Remains Industry-Wide Challenge
Executive Summary
Cash is still “cheap” but biopharma M&A continues to move slowly – mid-cap industry execs tell “The Pink Sheet” partly because there is so much competition to acquire the best assets. Meanwhile, most companies are economizing on R&D even as they strive to develop the products that will carry them into the next decade.